Tumor hypoxia has been extensively demonstrated in breast cancer [19] and expression of HIF1α represents an independent factor for poor prognosis in patients with lymph node-negative and -positive breast cancer, including several different subtypes [20,21,22,23,24]. This evidence concerns the gene HIF1A and breast carcinoma.